Ivabradine for Treating Chronic Heart Failure (TA267)

Technology Appraisal Guidance No. 267

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Ivabradine is recommended as an option for treating chronic heart failure for people:

  • with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction and
  • who are in sinus rhythm with a heart rate of 75 beats per minute (bpm) or more and
  • who are given ivabradine in combination with standard therapy including beta-blocker
  • therapy, angiotensin-converting enzyme (ACE) inhibitors and aldosterone antagonists, or when beta-blocker therapy is contraindicated or not tolerated and
  • with a left ventricular ejection fraction of 35% or less.

1.2 Ivabradine should only be initiated after a stabilisation period of 4 weeks on optimised standard therapy with ACE inhibitors, beta-blockers and aldosterone antagonists.

1.3 Ivabradine should be initiated by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist, or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA267

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:nice@nice.org.uk

Ivabradine for treating chronic heart failure
Issue Date: November 2012


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in